Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R03 - Clinical Trial Optional)
ID: 336480Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $50K

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/336480

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-21-354.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity through the R03 Small Grant Program for innovative screening approaches and therapies aimed at screenable disorders in newborns. This initiative encourages research on novel screening methods and therapeutic interventions for potentially fatal or disabling conditions identified through newborn screening, particularly focusing on "high priority" genetic conditions that could benefit from early detection. The program is crucial for enhancing newborn screening programs and improving health outcomes for infants, with a maximum funding amount of $50,000 available for each project over a two-year period. Interested applicants, including educational institutions, non-profits, and government organizations, must submit their proposals by November 16, 2024, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-21-354-Full-Announcement.html
    PAR-21-354.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), seeks proposals for the R03 Small Grant Program focusing on innovative screening methods and therapies for newborns with fatal or disabling conditions. This funding opportunity encourages research on “high priority” genetic conditions that may benefit from early identification through newborn screening. The maximum funding per project is $50,000 over a period of two years. The initiative aims to enhance newborn screening programs by developing new technologies and treatments, thereby improving outcomes for infants diagnosed with such conditions. Eligible applicants include educational institutions, non-profits, and government organizations, both domestic and international. This announcement is a reissue of a previous opportunity and emphasizes the importance of early detection and intervention, while providing researchers access to established resources like the Newborn Screening Translational Research Network (NBSTRN). Applications are evaluated based on significance, investigator qualifications, innovation, approach, and environment. Key dates for submissions are outlined, with an expiration date for this funding opportunity based on NIH appropriations, indicating its relevance in the context of federal support for health-related research initiatives.
    Similar Opportunities
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for innovative research aimed at developing screening approaches and therapies for screenable disorders in newborns, designated as R21 - Clinical Trial Optional. This initiative encourages projects that focus on creating novel screening techniques and therapeutic interventions for potentially fatal or disabling conditions identified through newborn screening, particularly emphasizing early diagnosis and treatment to improve health outcomes. The program is part of NIH's commitment to advancing public health and reducing health disparities, with a funding ceiling of $275,000 available over a two-year period. Interested applicants, including a diverse range of institutions and organizations, must submit their proposals by November 16, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns," aimed at developing novel screening techniques and therapeutic interventions for potentially fatal or disabling conditions identified through newborn screening. This initiative encourages diverse scientific research focused on improving screening technologies, therapeutic interventions, and preclinical testing, particularly for "high priority" genetic conditions that are not currently recommended for screening but could benefit from early identification and treatment. Eligible applicants include a wide range of organizations, such as educational institutions, community-based organizations, and tribal governments, with applications due by November 5, 2024. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-21-353.html.
    Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research into the natural history of disorders detectable through newborn screening, under the grant title "Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)." This initiative aims to enhance understanding of these disorders to support early identification and intervention, focusing on improving diagnostic accuracy, elucidating genetic and clinical heterogeneity, and exploring underlying mechanisms to inform treatment options. The funding is available for new, renewal, resubmission, or revision applications, with a maximum support period of five years and no cost-sharing requirement. Interested applicants, including various educational and community organizations, must submit proposals by January 7, 2025, and can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for assistance or further information.
    NICHD Small Research Grant Program (R03 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NICHD Small Research Grant Program (R03), which supports small clinical trials focused on basic experimental studies involving human participants. This funding opportunity aims to enhance understanding of fundamental phenomena without immediate application towards products or processes, aligning with the NICHD's mission in human development, behavior, and health. Grants are available for up to $50,000 in direct costs per year, with a maximum project duration of two years, and applications must be submitted by January 7, 2025. Interested applicants can find more information and application details at the NIH website or contact the NIH OER Webmaster at grantsinfo@nih.gov for assistance.
    NICHD Small Research Grant Program (R03 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NICHD Small Research Grant Program (R03 Clinical Trial Required) to support clinical trials that align with the mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). This grant program is designed to fund small research projects with a maximum budget of $50,000 in direct costs per year, for a duration of up to two years, focusing on areas such as human development, childhood development, and rehabilitation medicine. Eligible applicants include a diverse range of organizations, including higher education institutions, nonprofits, for-profits, and tribal governments, with all applications required to propose clinical trials and adhere to NIH submission guidelines. Interested parties should note that the application deadline is January 7, 2025, and can reach out to the NIH OER Webmaster at grantsinfo@nih.gov for further inquiries. More information can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PA-21-221.html.
    Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)" aimed at advancing research on congenital defects linked to genetic variants. This initiative encourages the use of cutting-edge genotyping and sequencing technologies to validate genetic variants identified through public databases, bridging the gap between variant identification and understanding their functional impacts on developmental outcomes. The funding is available to a diverse range of eligible organizations, including higher education institutions and nonprofits, with an annual budget cap of $499,999 and a project period of up to five years. Interested applicants should contact the NIH OER Webmaster at grantsinfo@nih.gov for assistance and must submit their proposals by May 7, 2025, to be considered for this significant funding opportunity.
    Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering small research grants under the Gabriella Miller Kids First Pediatric Research Program, aimed at analyzing genomic and phenotypic data related to childhood cancers and structural birth defects. This funding opportunity encourages innovative research projects that utilize Kids First data, with a focus on developing analytical approaches, tools, or algorithms to enhance understanding and treatment of pediatric conditions. The initiative is part of a broader effort to leverage genomics for precision medicine in pediatric healthcare, with a maximum funding amount of $200,000 available for projects lasting up to two years. Interested applicants can find more information and apply by visiting the program's webpage or contacting NIH Grants Information at grantsinfo@nih.gov, with applications due by January 7, 2026.
    NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Small Research Grant Program (Parent R03 Clinical Trial Not Allowed) to support small-scale research projects that can be completed in a short timeframe with limited resources. This program is designed to fund various types of research, including pilot studies, secondary data analysis, and the development of research methodologies, while explicitly excluding clinical trials. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and tribal governments, with each application allowed to request up to $50,000 per year for a project duration not exceeding two years. Interested parties should submit their applications electronically via Grants.gov by January 7, 2025, and can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for any inquiries regarding the funding announcement.
    SBIR Solutions to Enable Population Genomic Screening (R43/R44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "SBIR Solutions to Enable Population Genomic Screening," aimed at soliciting Small Business Innovation Research (SBIR) grant applications from U.S. small businesses. The objective of this initiative is to develop innovative solutions that facilitate population genomic screening for common, actionable genomic conditions within primary care settings, addressing significant barriers such as logistical challenges, provider education, and follow-up procedures. This program is crucial for enhancing the readiness of primary care providers to manage genomic screening, particularly for conditions like hereditary breast cancer and Lynch syndrome. Grants of up to $400,000 are available for Phase I applications, with Phase II grants potentially reaching $2.15 million. Interested applicants should note that the submission window opens on November 1, 2024, with a deadline for applications set for December 2, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed)" aimed at stimulating innovation in the implementation and sharing of genomic information in clinical care across diverse populations. This initiative encourages applications for small research projects that explore the integration of genomic data into clinical practice, assess barriers to implementation, and develop innovative data analysis techniques, particularly focusing on underrepresented populations in genomic research. The maximum budget for each application is $50,000 over a two-year period, with a total funding expectation of approximately $150,000 for FY 2024. Interested applicants must submit their proposals by February 12, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.